Brief: Kaleido Biosciences Says First Patient Dosed In Clinical Study Of Microbiome Metabolic Therapy Kb295 In Patients With Mild-To-Moderate Ulcerative Colitis
29/09/2020 12:40
Sept 29 (Reuters) - Kaleido Biosciences Inc KLDO.O :
* KALEIDO BIOSCIENCES ANNOUNCES FIRST PATIENT DOSED IN
CLINICAL
STUDY OF MICROBIOME METABOLIC THERAPY KB295 IN PATIENTS WITH
MILD-TO-MODERATE ULCERATIVE COLITIS
* KALEIDO BIOSCIENCES INC - TOP-LINE DATA FROM STUDY
EXPECTED IN
MID-2021
Source text for Eikon: ID:nGNX4KSrm9
Further company coverage: KLDO.O
((Reuters.Briefs@thomsonreuters.com;))